Clinical Outcomes of Anti-VEGF Monotherapy Versus Combination Therapy in Diabetic Macular Edema: A Retrospective Cohort Study
Journal of Visualized Experiments · 2026
DOI: 10.3791/70675 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2026. Written by Lei Xi and 2 co-authors. Institution: Department of Ophthalmology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University. Major MEDLINE topics: Macular Edema, Vascular Endothelial Growth Factor A, Diabetic Retinopathy, Angiogenesis Inhibitors. 38 references.
Abstract (original language)
Diabetic macular edema (DME) is a leading cause of blindness involving vascular endothelial growth factor (VEGF) leakage and inflammation. This retrospective, single-center cohort study evaluated the efficacy and safety of intravitreal anti-VEGF monotherapy versus combination therapy with anti-VEGF plus dexamethasone implant in DME. A total of 200 patients (one eye per patient) treated between January 2021 and December 2024 were included, with 100 receiving anti-VEGF monotherapy and 100 receiving combination therapy. Best-corrected visual acuity (BCVA), central macular thickness (CMT), adverse events, and quality of life (NEI-VFQ-25) were assessed at baseline and at 1, 3, and 6 months. At 1 and 3 months, the combination therapy group showed faster improvement in BCVA (0.53±0.14 vs. 0.61±0.14 at 1 month; 0.46±0.13 vs. 0.53±0.12 at 3 months) and CMT (342±52 µm vs. 380±55 µm at 1 month; 315±48 µm vs. 345±50 µm at 3 months) compared with the monotherapy group (all P < 0.05), along with a higher rapid response rate (68.0% vs. 42.0%, P < 0.001). However, these differences were no longer significant at 6 months. The combination therapy group had higher rates of elevated intraocular pressure (18% vs. 6%, P < 0.05) and cataract progression (12% vs. 3%, P < 0.05). In conclusion, combination therapy was associated with faster early improvement in visual acuity and macular edema resolution within the first 3 months, but this early advantage was not sustained at 6 months and was accompanied by increased risks of elevated intraocular pressure and cataract progression.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University.
- Department of Ophthalmology, Huizhou Third People's Hospital, Guangzhou Medical University.
- Zhongshan Ophthalmic Center, Sun Yat-sen University, (State Key Laboratory of Ophthalmology), (Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science); zhaofeng1022@hotmail.com.
Cite
APA
Xi, L., Li, W., & Zhao, F. (2026). Clinical Outcomes of Anti-VEGF Monotherapy Versus Combination Therapy in Diabetic Macular Edema: A Retrospective Cohort Study. Journal of Visualized Experiments. https://doi.org/10.3791/70675
Vancouver
Xi L, Li W, Zhao F. Clinical Outcomes of Anti-VEGF Monotherapy Versus Combination Therapy in Diabetic Macular Edema: A Retrospective Cohort Study. Journal of Visualized Experiments. 2026. doi:10.3791/70675
BibTeX
@article{Xi2026,
author = {Xi, Lei and Li, Wentao and Zhao, Feng},
title = {Clinical Outcomes of Anti-VEGF Monotherapy Versus Combination Therapy in Diabetic Macular Edema: A Retrospective Cohort Study},
journal = {Journal of Visualized Experiments},
year = {2026},
doi = {10.3791/70675}
}
EUVIMED